TICKERNERD
Menu
NRIXNRIXHealthcare · Biotechnology

NRIX Stock Forecast: Nurix Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$23
+0.04% on the day

The 15 Wall Street analysts covering Nurix Therapeutics, Inc. hold a median 12-month price target of $34 — +44.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 45 of 100 as at 1 Aug 2026 — in the lower half.

Market cap
$2.4B
Ticker Nerd rank
45 / 100
Median analyst target
$34
Analysts covering
15
Total return, dividends reinvested
1W
−0.9%
1M
−3.1%
YTD
+22.4%
1Y
+110.3%
From 52W high
−6.0%
From 52W low
+181.8%
$8
$25
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

NRIX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Nurix Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
45 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
94
Revisions
71
Volatility
65
Accruals
61
Value
52
Size
34
Quality
30
Growth
24
Issuance
18

Momentum (94): The shares have been drifting up relative to others.

Issuance (18): The company has been issuing shares or taking on financing, diluting existing holders.

The rank is the raw material. Whether the rules would actually own Nurix Therapeutics, Inc. — and when they’d sell — is the membership.

Wall Street

NRIX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NRIX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50Oct 25Jan 26Apr 26Jul 26NRIXHigh $45Median $34Low $25

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says15 analysts
14 Buy1 Hold0 Sell
Low $25Median $34High $45

The green dot is the last close — the median target sits +44.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 7 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
28 July 2026Morgan StanleyMaintainsOverweight$36 → $38
22 July 2026UBSMaintainsBuy$23 → $31
13 July 2026MizuhoMaintainsOutperform—
13 July 2026MizuhoMaintainsOutperform$30 → $34
10 July 2026BTIGReiteratesBuy$32
10 July 2026BTIGReiteratesBuy—
10 July 2026HC Wainwright & Co.MaintainsBuy$32 → $34
10 July 2026HC Wainwright & Co.MaintainsBuy—
10 July 2026NeedhamReiteratesBuy$34
10 July 2026NeedhamReiteratesBuy—
10 July 2026RBC CapitalMaintainsOutperform—
10 July 2026RBC CapitalMaintainsOutperform$30 → $33
10 July 2026StifelMaintainsBuy$34 → $40
10 July 2026StifelMaintainsBuy—
10 July 2026Truist SecuritiesMaintainsBuy$32 → $34
10 July 2026Truist SecuritiesMaintainsBuy—
18 June 2026BairdMaintainsOutperform—
15 June 2026NeedhamReiteratesBuy—
10 June 2026HC Wainwright & Co.ReiteratesBuy—
9 June 2026BTIGMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

NRIX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
3
Analysts cutting
1
Fundamentals

Nurix Therapeutics, Inc. (NRIX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−7.6×

Cheaper than 91% of US stocks

Price / sales
65.5×

Cheaper than 5% of US stocks

Price / book
6.0×

Cheaper than 18% of US stocks

EV / EBITDA
−5.7×

Cheaper than 80% of US stocks

Growth & margins
Revenue growth (YoY)
−79.5%

Higher than 3% of US stocks

Earnings growth (YoY)
−79.5%

Higher than 5% of US stocks

Gross margin
—
Operating margin
−1041.7%

Higher than 6% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−80.3%

Higher than 16% of US stocks

Return on assets
−40.1%

Higher than 10% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

NRIX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
NRIXNurix Therapeutics, Inc.$2.4B
45
NKTRNektar Therapeutics$2.3B
52
VCELVericel Corp.$2.3B
94
PHVSPharvaris NV$2.3B
46
RAREUltragenyx Pharmaceutical, Inc.$2.5B
38
MLYSMineralys Therapeutics, Inc.$2.2B
37
VERAVera Therapeutics, Inc.$2.2B
22
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NRIX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest NRIX news & analysis

Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

GlobeNewsWire · 4 Aug 2026positive

Nurix Therapeutics announced that the first patient has been enrolled in its registrational Phase 3 DAYBreak CLL-306 trial evaluating bexobrutideg in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma who were previously treated with a covalent BTK inhibitor.

Why it matters — This milestone moves bexobrutideg into a registrational trial designed to show superiority over an existing treatment, which if successful could support a regulatory filing and expand Nurix's pipeline value.

FAQ

Frequently asked questions about NRIX stock

What is the NRIX stock price forecast for 2026-2027?

The 15 Wall Street analysts covering Nurix Therapeutics, Inc. have a median 12-month price target of $34, with estimates ranging from $25 to $45. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NRIX stock a buy right now?

Of the 15 analysts covering Nurix Therapeutics, Inc., 14 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Nurix Therapeutics, Inc. 45 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NRIX?

As at 1 Aug 2026, Nurix Therapeutics, Inc. ranks 45 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (94 of 100).

Will NRIX stock go up?

No one can know that. What the data says: the median 12-month target from 15 analysts implies +44.3% from the last close, and Ticker Nerd's factor model ranks Nurix Therapeutics, Inc. 45 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NRIX stock forecast for 2030?

No analyst covering Nurix Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NRIX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $25 to $45 over the next 12 months.

How has NRIX stock performed over the past year?

Nurix Therapeutics, Inc. returned +110.3% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Nurix Therapeutics, Inc. do?

Nurix Therapeutics Inc. is a biotechnology firm focused on developing therapies to address immune system disorders and cancers.

What is the latest news on NRIX?

The most recent item we track (GlobeNewsWire, 4 Aug 2026): "Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma". Nurix Therapeutics announced that the first patient has been enrolled in its registrational Phase 3 DAYBreak CLL-306 trial evaluating bexobrutideg in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma who were previously treated with a covalent BTK inhibitor.

Company

About Nurix Therapeutics, Inc.

Nurix Therapeutics Inc. is a biotechnology firm focused on developing therapies to address immune system disorders and cancers. At the heart of its innovative approach is the modulation of protein levels within cells, a critical factor in disease progression. Nurix employs its proprietary DELigase platform to discover and design targeted therapies that either enhance or degrade specific proteins through ubiquitin proteasome system engagement. By manipulating the protein degradation pathways, the company aims to offer new treatment paradigms where traditional therapeutics may fall short. Nurix Therapeutics' research and product pipeline significantly influences the biotechnology and pharmaceutical sectors, with emphasis on immuno-oncology, a rapidly growing field within cancer treatment. Formed through scientific expertise and collaborations, the company encapsulates significant market insights by translating breakthroughs in protein homeostasis into potential life-altering therapies, thus playing a pivotal role in advancing personalized medicine.

CEO Dr. Arthur T. Sands M.D., Ph.D. · 317 employees · United States · https://www.nurixtx.com